Cited 3 times in
Non-vitamin K oral anticoagulants as first-line regimen for acute ischemic stroke with non-valvular atrial fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김영대 | - |
dc.contributor.author | 남효석 | - |
dc.contributor.author | 박찬욱 | - |
dc.contributor.author | 박형종 | - |
dc.contributor.author | 이혜선 | - |
dc.contributor.author | 허지회 | - |
dc.date.accessioned | 2020-12-01T17:09:00Z | - |
dc.date.available | 2020-12-01T17:09:00Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 1052-3057 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180145 | - |
dc.description.abstract | Purpose: There are various patterns in determining the choice of the first-line antithrombotic agent for acute stroke with non-valvular atrial fibrillation. We investigated the efficacy and safety of non-vitamin K oral anticoagulants as first-line antithrombotics for patients with acute stroke and non-valvular atrial fibrillation. Materials and methods: Patients with non-valvular atrial fibrillation and ischemic stroke or transient ischemic attack within 24 h from stroke onset were included. On the basis of the first regimen used and the regimen within 7 days after admission, the study population was divided into three groups: 1) antiplatelet switched to warfarin (A-W), 2) antiplatelet switched to NOAC (A-N), and 3) NOAC only (N only). We compared the occurrence of early neurologic deterioration, symptomatic intracranial hemorrhage, systemic bleeding, and poor functional outcome at 90 days. Results: Of 314 included patients, 164, 53, and 97 were classified into the A-W, A-N, and N only groups, respectively. Early neurologic deterioration was most frequently observed in the A-W group (9.1%), followed by the A-N (5.7%) and N only (1.0%) groups (p = 0.017). Multivariable analysis adjusting for potential confounders demonstrated that the N only group was independently associated with a lower rate of early neurologic deterioration (odds ratio [OR] 0.104, 95% CI 0.013-0.831) or poor functional outcome at 90 days (OR 0.450, 95% CI 0.215-0.940) than the A-W group. However, the rate of symptomatic intracranial hemorrhage or any systemic bleeding event did not differ among the groups. Conclusion: Using non-vitamin K oral anticoagulants as the first-line regimen for acute ischemic stroke may help prevent early neurologic deterioration without increasing the bleeding risk. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Saunders | - |
dc.relation.isPartOf | JOURNAL OF STROKE & CEREBROVASCULAR DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Anticoagulants / administration & dosage* | - |
dc.subject.MESH | Anticoagulants / adverse effects | - |
dc.subject.MESH | Atrial Fibrillation / complications | - |
dc.subject.MESH | Atrial Fibrillation / diagnosis | - |
dc.subject.MESH | Atrial Fibrillation / drug therapy* | - |
dc.subject.MESH | Brain Ischemia / diagnosis | - |
dc.subject.MESH | Brain Ischemia / drug therapy* | - |
dc.subject.MESH | Brain Ischemia / etiology | - |
dc.subject.MESH | Disability Evaluation | - |
dc.subject.MESH | Drug Substitution* / adverse effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intracranial Hemorrhages / chemically induced | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / administration & dosage* | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / adverse effects | - |
dc.subject.MESH | Recovery of Function | - |
dc.subject.MESH | Registries | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Stroke / diagnosis | - |
dc.subject.MESH | Stroke / drug therapy* | - |
dc.subject.MESH | Stroke / etiology | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Warfarin / administration & dosage* | - |
dc.subject.MESH | Warfarin / adverse effects | - |
dc.title | Non-vitamin K oral anticoagulants as first-line regimen for acute ischemic stroke with non-valvular atrial fibrillation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학교실) | - |
dc.contributor.googleauthor | Chan Wook Park | - |
dc.contributor.googleauthor | Hyo Suk Nam | - |
dc.contributor.googleauthor | Ji Hoe Heo | - |
dc.contributor.googleauthor | Hyung Jong Park | - |
dc.contributor.googleauthor | Jin Kyo Choi | - |
dc.contributor.googleauthor | Hye Sun Lee | - |
dc.contributor.googleauthor | Han Kyu Na | - |
dc.contributor.googleauthor | Young Dae Kim | - |
dc.identifier.doi | 10.1016/j.jstrokecerebrovasdis.2020.105025 | - |
dc.contributor.localId | A00702 | - |
dc.contributor.localId | A01273 | - |
dc.contributor.localId | A05541 | - |
dc.contributor.localId | A05600 | - |
dc.contributor.localId | A03312 | - |
dc.contributor.localId | A04369 | - |
dc.relation.journalcode | J01759 | - |
dc.identifier.eissn | 1532-8511 | - |
dc.identifier.pmid | 32807440 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1052305720304432 | - |
dc.subject.keyword | Anticoagulant | - |
dc.subject.keyword | Atrial fibrillation | - |
dc.subject.keyword | Cerebral infarction | - |
dc.subject.keyword | Outcome | - |
dc.contributor.alternativeName | Kim, Young Dae | - |
dc.contributor.affiliatedAuthor | 김영대 | - |
dc.contributor.affiliatedAuthor | 남효석 | - |
dc.contributor.affiliatedAuthor | 박찬욱 | - |
dc.contributor.affiliatedAuthor | 박형종 | - |
dc.contributor.affiliatedAuthor | 이혜선 | - |
dc.contributor.affiliatedAuthor | 허지회 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 105025 | - |
dc.identifier.bibliographicCitation | JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, Vol.29(9) : 105025, 2020-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.